TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34454420

Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Mild pain
Number of subjects: 1777
Study: 34454432

Group type: EXPERIMENTAL
Intervention: Zika virus infection
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Unidentified pathogen (UIE)
Number of subjects: 427
Study: 34454460

Group type: EXPERIMENTAL
Intervention: Hamstring muscle evaluation at velocities of 60 and 180 deg/s
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hamstring muscle evaluation in patients with one-sided dislocation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Knee flexors strength evaluation in recurrent patellar dislocation patients
Number of subjects: 33
Study: 34454573

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) sessions, exercising at 30% of MIP, two daily sessions for 3 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional neurorehabilitation (usual practice)
Number of subjects: 80
Study: 34454591

Group type: EXPERIMENTAL
Intervention: 2-HOBA
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 34454592

Group type: EXPERIMENTAL
Intervention: TIMP with rhythm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TIMP without rhythm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard of care occupational therapy (OT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlisted (control)
Number of subjects: 100
Study: 34454594

Group type: EXPERIMENTAL
Intervention: Standard usual care combined with in-bed cycling
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Standard usual care combined with exercises from a booklet
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard usual care
Number of subjects: 210
Study: 34454636

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 31
Study: 34454637

Group type: EXPERIMENTAL
Intervention: Deliberative loop intervention with stakeholders (providers and staff) including background information, facilitated small-group discussions, and sharing informed opinions with clinic leaders.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Deliberative loop intervention
Number of subjects: 16
Study: 34454787

Group type: EXPERIMENTAL
Intervention: ACAM2000 smallpox vaccine
Number of subjects: 897227

Group type: COMPARATOR
Intervention: Dryvax smallpox vaccine
Number of subjects: 897227
Study: 34454994

Group type: EXPERIMENTAL
Intervention: PRO-C3
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: ADAPT
Number of subjects: 517
Study: 34455067

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort C)
Number of subjects: 93
Study: 34455112

Group type: EXPERIMENTAL
Intervention: Lipid-rich plaques detected by near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS)
Number of subjects: 1551

Group type: COMPARATOR
Intervention: Age groups (<50, 50-64, 65-74, ≥75)
Number of subjects: 1551
Study: 34455263

Group type: EXPERIMENTAL
Intervention: Folate supplementation (n = 168)
Number of subjects: 379

Group type: COMPARATOR
Intervention: No folate supplementation (n = 184)
Number of subjects: 379
Study: 34455857

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bioprosthetic surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 34456057

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 565
Study: 34457038

Group type: EXPERIMENTAL
Intervention: Oral masitinib (4.5 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34457743

Group type: EXPERIMENTAL
Intervention: One-day laparoscopic skills workshop
Number of subjects: 33
Study: 34457749

Group type: EXPERIMENTAL
Intervention: UTHealth trainees
Number of subjects: 3248
Study: 34457876

Group type: EXPERIMENTAL
Intervention: BLS training with preparatory web-based education, instructor-led training, film-based instructions, reflective questions, and chest compression feedback device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard BLS training
Number of subjects: 0
Study: 34458156

Group type: EXPERIMENTAL
Intervention: Stool consistency measured by the Bristol Stool Scale (BSS) and fecal dry weight percentage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Microbial community structure analysis (beta diversity)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single fecal sampling
Number of subjects: 24
Study: 34458717

Group type: EXPERIMENTAL
Intervention: Injection port of ported PVCs
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Internal lumen of ported PVCs
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both port and internal lumen of ported PVCs
Number of subjects: 300
Study: 34459237

Group type: EXPERIMENTAL
Intervention: Prolonged high-intensity endurance exercise (first race)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (least strenuous exercise)
Number of subjects: 59
Study: 34459317

Group type: EXPERIMENTAL
Intervention: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus vaccine
Number of subjects: 162
Study: 34459500

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI) / Accelerated partial breast irradiation (APBI)
Number of subjects: 15187
Study: 34460083

Group type: EXPERIMENTAL
Intervention: NaIHS (50 mg ibuprofen, tid)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 383
Study: 34460829

Group type: EXPERIMENTAL
Intervention: SD Bioline HAT
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: HAT Sero-K-Set
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: rHAT Sero-Strip
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: LAMP and ELISA/Tbg
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: Diagnostic tests (general)
Number of subjects: 3433
Study: 34461299

Group type: EXPERIMENTAL
Intervention: PBC patients
Number of subjects: 112
Study: 34461303

Group type: EXPERIMENTAL
Intervention: History of smoking and/or alcohol consumption (positive gene mutation group)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: History of smoking and/or alcohol consumption (negative gene mutation group)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Patients with gene mutations (with and without alcohol/smoking status)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Age at onset of CP
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 798
Study: 34461561

Group type: EXPERIMENTAL
Intervention: High eicosapentaenoic acid multinutrient supplement (1125 mg eicosapentaenoic acid, 441 mg docosahexaenoic acid, 330 mg magnesium, 7.5 mg vitamin E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34461936

Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) recommendations based on pre-pregnancy BMI
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: GWG of ≥14 kg and <16 kg
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: GWG of ≥10 kg and <12 kg
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: GWG of ≥12 kg and <14 kg
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for underweight women
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for normal weight women
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for overweight women
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for obese women
Number of subjects: 3172
Study: 34462004

Group type: EXPERIMENTAL
Intervention: Self-sampling (urine and vaginal)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Self-sampling (urine)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Self-sampling (vaginal with cotton swabs)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Self-sampling (vaginal with plastic brushes)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 515

Group type: COMPARATOR
Intervention: Clinician-collected sample
Number of subjects: 515
Study: 34462007

Group type: EXPERIMENTAL
Intervention: Ketamine infusion 1-2 μg/kg/min for 48 hours
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard of care alone (Control Group)
Number of subjects: 83
Study: 34462008

Group type: EXPERIMENTAL
Intervention: Tailored discussion guide (TDG) and brief provider training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 44
Study: 34462189

Group type: EXPERIMENTAL
Intervention: GLS-010 (zimberelimab) 240 mg, intravenous, once every 2 weeks until progression, death, unacceptable toxicity, or consent withdrawal
Number of subjects: 85
Study: 34462238

Group type: EXPERIMENTAL
Intervention: Growth hormone withdrawal
Number of subjects: 10
Study: 34462271

Group type: EXPERIMENTAL
Intervention: Digital service model for high-risk COPD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standards of care
Number of subjects: 0
Study: 34462327

Group type: EXPERIMENTAL
Intervention: Bintrafusp alpha (dual PD-L1 and TGF-b blockade)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Avelumab (PD-L1 blockade)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TGF-b neutralization
Number of subjects: 8

Group type: COMPARATOR
Intervention: PD-L1 blockade alone
Number of subjects: 8
Study: 34462560

Group type: EXPERIMENTAL
Intervention: Predictive equations (PEs) developed from acute phase data using indirect calorimetry measurements.
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Best predictive equation for REE: 891.6(Height) + 9.0(Weight) + 39.7(Minute Ventilation) - 5.6(Age) - 354.
Number of subjects: 474
Study: 34462732

Group type: EXPERIMENTAL
Intervention: icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 100
Study: 34462760

Group type: EXPERIMENTAL
Intervention: CD24Fc treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34463622

Group type: EXPERIMENTAL
Intervention: WYZ mobile health app
Number of subjects: 79
Study: 34463717

Group type: EXPERIMENTAL
Intervention: LAA filling defects
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Normal LAA filling
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: Thrombus-like pattern
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: HU-run-off pattern
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: Heterogeneous pattern
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: Horizontal pattern
Number of subjects: 1621
Study: 34463835

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) intervention, delivered twice a week for 3 months, consisting of 1 hour of TE and 30 minutes of nutritional education
Number of subjects: 158
Study: 34463905

Group type: EXPERIMENTAL
Intervention: Patients with TRD
Number of subjects: 1475

Group type: COMPARATOR
Intervention: Patients without TRD
Number of subjects: 1475
Study: 34464029

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg q.d.
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg q.d.
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1916
Study: 34464155

Group type: EXPERIMENTAL
Intervention: AUTO1 (autologous CAT19-41BB-Z CAR T cells)
Number of subjects: 20
Study: 34464163

Group type: EXPERIMENTAL
Intervention: Intratumoral Coxsackievirus A21 (V937)
Number of subjects: 57
Study: 34464408

Group type: EXPERIMENTAL
Intervention: Risk-group with preterm birth (RG-PB)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Risk-group with term birth (RG-TB)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Planned delivery mode
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Medical support and positive childbirth experience
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Positive birth experience
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Path modeling
Number of subjects: 284
Study: 34464523

Group type: EXPERIMENTAL
Intervention: Equine-Assisted Therapy
Number of subjects: 0
Study: 34464547

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted arcuate incisions using the Castrop nomogram
Number of subjects: 19
Study: 34464961

Group type: EXPERIMENTAL
Intervention: DFOS-IT
Number of subjects: 265
Study: 34465123

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary score
Number of subjects: 10385

Group type: EXPERIMENTAL
Intervention: KCCQ subdomains
Number of subjects: 10385

Group type: EXPERIMENTAL
Intervention: KCCQ scores
Number of subjects: 10385
Study: 34465132

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-power, short-duration radiofrequency ablation
Number of subjects: 0
Study: 34465131

Group type: EXPERIMENTAL
Intervention: Preimplant Perceived Stress Scale score
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 6 months Perceived Stress Scale score
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Factors associated with higher Perceived Stress Scale score at 6 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Qualitative analysis themes
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Coping strategies employed by caregivers
Number of subjects: 96
Study: 34465185

Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Rural patients (after adjusting for demographics, depression severity, and physical functioning)
Number of subjects: 628
Study: 34465306

Group type: EXPERIMENTAL
Intervention: Weekly voluntary screening for SARS-CoV-2 with a high sensitivity molecular-based saliva test
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Mitigation strategies including higher than expected student mask compliance, reduced room capacity, and phased reopening
Number of subjects: 475
Study: 34465348

Group type: EXPERIMENTAL
Intervention: Patients without new in-brace x-rays with major brace adjustments or new brace fabrication
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patients with new in-brace x-rays with major brace adjustments or new brace fabrication
Number of subjects: 90
Study: 34465452

Group type: EXPERIMENTAL
Intervention: Prolonged cyclical treatment regimen of dydrogesterone 10 mg 2 or 3 times daily between the 5th and 25th days of the menstrual cycle
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Continuous treatment regimen of dydrogesterone 10 mg 2 or 3 times daily
Number of subjects: 350

Group type: COMPARATOR
Intervention: Both treatment regimens (prolonged cyclical and continuous)
Number of subjects: 350
Study: 34465457

Group type: EXPERIMENTAL
Intervention: Nonculprit lipid-rich plaques identified by near-infrared spectroscopy (maxLCBI)
Number of subjects: 0
Study: 34465465

Group type: EXPERIMENTAL
Intervention: Automated ECG interpretation statements of acute MI or acute ischemia
Number of subjects: 2400
Study: 34465599

Group type: EXPERIMENTAL
Intervention: LY3300054 monotherapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LY3300054/anti-TIM-3 combination
Number of subjects: 82
Study: 34465694

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 8, 12, or 24 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Number of subjects: 95
Study: 34466220

Group type: EXPERIMENTAL
Intervention: Antegrade ureteral stent insertion
Number of subjects: 188
Study: 34466711

Group type: EXPERIMENTAL
Intervention: Nurse-implemented chronotherapeutic restoring bundle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34466766

Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Continuation of immunotherapy, surgery, external beam radiation
Number of subjects: 1
Study: 34467247

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34467254

Group type: EXPERIMENTAL
Intervention: Dual blockade of α4β7 and αEβ7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etrolizumab treatment
Number of subjects: 0
Study: 34467476

Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: gBRCA1 mutations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: gBRCA2 mutations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations in hormone receptor-positive MBC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations in triple-negative MBC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HRR gene mutations
Number of subjects: 104
Study: 34467530

Group type: COMPARATOR
Intervention: Intravenous atosiban
Number of subjects: 3733

Group type: COMPARATOR
Intervention: Subcutaneous barusiban
Number of subjects: 3733

Group type: COMPARATOR
Intervention: Oral nolasiban
Number of subjects: 3733
Study: 34467774

Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (TRODELVY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 0
Study: 34468322

Group type: EXPERIMENTAL
Intervention: RECAP-V1 prediction model
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: External validation on an independent dataset of 1400 patients
Number of subjects: 3732
Study: 34468330

Group type: EXPERIMENTAL
Intervention: About Us intervention
Number of subjects: 533

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 533
Study: 34468332

Group type: EXPERIMENTAL
Intervention: The Secret Trail of Moon (TSTM) - a virtual reality serious video game for cognitive training related to ADHD symptoms.
Number of subjects: 37
Study: 34468913

Group type: EXPERIMENTAL
Intervention: Capnometry Guided Respiratory Intervention (CGRI)
Number of subjects: 0
Study: 34468953

Group type: EXPERIMENTAL
Intervention: Concurrent meningitis and extra-cerebral IPD
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Overall IPD
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Older age, history of malignant solid tumor, meningeal IPD, and serotypes with high mortality potential
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Non-vaccine serotypes
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Meningitis patients
Number of subjects: 771
Study: 34468963

Group type: EXPERIMENTAL
Intervention: Antifungal therapy (voriconazole alone or sequential/combined therapy)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Antifungal therapy (voriconazole)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Optimal voriconazole regimen (loading dose, 200 mg twice daily; daily maintenance dose, 100 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: ACLF patients with IPA
Number of subjects: 145
Study: 34468973

Group type: EXPERIMENTAL
Intervention: Total PHMS (Philadelphia Mindfulness Scale)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PHMS-Acceptance
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PHMS-Awareness
Number of subjects: 108
Study: 34469268

Group type: EXPERIMENTAL
Intervention: Prospective observation of mild and moderate asthma
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Treatments over time
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Disease-related functional and inflammatory patterns
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Environmental and lifestyle influences
Number of subjects: 20000
Study: 34470049

Group type: EXPERIMENTAL
Intervention: Venetoclax 800 mg, Carfilzomib 70 mg/m2, Dexamethasone 40 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 or 800 mg, Carfilzomib 27, 56, or 70 mg/m2, Dexamethasone 20 or 40 mg
Number of subjects: 49
Study: 34470054

Group type: EXPERIMENTAL
Intervention: Regular transfusion in adults
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Genotype in children
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Iron chelation
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Jaundice symptom
Number of subjects: 254
Study: 34470489

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) with complete recanalization
Number of subjects: 248
Study: 34470501

Group type: EXPERIMENTAL
Intervention: Catheter-based alcohol-mediated renal denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34470614

Group type: EXPERIMENTAL
Intervention: Maternal age 30 years or older
Number of subjects: 8509

Group type: EXPERIMENTAL
Intervention: Optimal BMI status and consistent multivitamin supplement intake
Number of subjects: 8509
Study: 34470657

Group type: EXPERIMENTAL
Intervention: Mobilisation from supine to standing position
Number of subjects: 24
Study: 34470703

Group type: EXPERIMENTAL
Intervention: High-Sensitivity Cardiac Troponin I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34470826

Group type: EXPERIMENTAL
Intervention: Δ40p53 isoform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netrin-1 interference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netrin-1 and Δ40p53 gene expression correlation
Number of subjects: 0
Study: 34471234

Group type: EXPERIMENTAL
Intervention: CXCR4 and anti-BCMA CAR co-modified NK cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34471346

Group type: EXPERIMENTAL
Intervention: Asymmetrical surgery for esotropia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Symmetrical surgery for esotropia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Asymmetrical surgery for exotropia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Symmetrical surgery for exotropia
Number of subjects: 40
Study: 34471447

Group type: EXPERIMENTAL
Intervention: Intraoperative Electro-Auricular Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuraxial Anesthesia
Number of subjects: 0